Skip to content
Clinical Trials – home

Johannes Kepler University

Verifiedinfo

Austria Med Campus III, Krankenhausstrasse 9, 4020 Linz, Austria

  • 48 trials recruiting
  • Idiopathic pulmonary fibrosis · Colitis ulcerative · Crohn's disease
  • Adults and children

About Specializations

Johannes Kepler University in Linz, Austria specialises in clinical trials of conditions such as Idiopathic pulmonary fibrosis, Colitis ulcerative, Crohn's disease, Partial seizures, and other specialisations. This site conducts important research.

Main research areas of the site

Cardiovascular Diseases Research

At Johannes Kepler University in Linz, the Department of Surgery Division of Cardiac Surgery is involved in studies focused on cardiovascular diseases, especially coronary artery disease. The trials are designed to assess whether new treatment strategies can improve heart-related outcomes and reduce complications after surgery.

  • Evaluating a treatment approach for patients undergoing coronary artery bypass grafting
  • Studying ways to lower the risk of ischemic events and graft failure
  • Comparing the effectiveness of different antiplatelet strategies

These investigations aim to improve recovery, long-term protection, and overall treatment effectiveness in people with serious heart disease.

Neoplasms Research

The site is also contributing to clinical research in neoplasms, with a strong focus on melanoma and Ewing sarcoma. The goal of this work is to test new cancer treatment strategies and improve survival outcomes for patients with advanced or high-risk disease.

  • Testing a new therapy approach for previously treated advanced melanoma
  • Exploring treatment optimization in Ewing sarcoma
  • Assessing whether therapy combinations can improve overall survival and event-free survival

These studies reflect an active effort to refine cancer care and identify more effective options for difficult-to-treat tumors.

Hormonal Diseases Research

Clinical trials in hormonal diseases at this educational institution include research on growth hormone deficiency. The main purpose is to better understand treatment effects on growth outcomes and how closely patients can reach their expected adult height.

  • Studying growth hormone deficiency in children and adolescents
  • Comparing growth-related outcomes between treatment groups
  • Evaluating whether therapy can improve final height results

This research helps clarify the impact of treatment on growth and supports more personalized care for patients with endocrine disorders.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Med Campus III, Krankenhausstrasse 94020 LinzAustria
Recruiting now
48 trials
Conditions studied
76
Partner status
Verified

More sites in LinzAustria

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

78 clinical trials

Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Golimumab
  • Sponsor:Janssen Cilag International
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:SPY002
  • Sponsor:Spyre Therapeutics Inc.
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Duvakitug
  • Sponsor:Sanofi-Aventis Recherche & Developpement
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Duvakitug
  • Sponsor:Sanofi-Aventis Recherche & Developpement
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:SPY002
  • Sponsor:Spyre Therapeutics Inc.
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:Medica Scientia Innovation Research S.L.
Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Spesolimab
  • Sponsor:Leo Pharma A/S
Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Amlitelimab
  • Sponsor:Scleroderma Research Foundation
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Bhv-7000
  • Sponsor:Biohaven Therapeutics Ltd.

Narcolepsy

Recruiting
Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:N-{(2S,3R)-4,4-Difluoro-1-(2-Hydroxy-2-Methylpropanoyl)-2-[(2,3',5'-Trifluoro[1,1'-Biphenyl]-3-Yl)Methyl]Pyrrolidin-3-Yl}Ethanesulfonamide
  • Sponsor:Takeda Development Center Americas Inc.
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Golimumab
  • Sponsor:Janssen Cilag International
Is this your site?

Join our network of research sites

Move up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.